Evidence map›Paper›PMID 29345365›Full record

ArticleJournal of leukocyte biology2018

Deletion of BCG Hip1 protease enhances dendritic cell and CD4 T cell responses.

Erica Bizzell, Jonathan Kevin Sia, Melanie Quezada, Ana Enriquez, Maria Georgieva, Jyothi Rengarajan

Abstract read
In one paragraph

Article in Journal of leukocyte biology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Glucose metabolism and its role in the maturation and migration of human CD1cFrontiers in cellular and infection microbiology · 2023
    Article
  5. iScience · 2022
    Article
  6. Article
  7. Review
  8. Advancing Adjuvants forFrontiers in immunology · 2021
    Review
  9. Immunology ofMicrobiology spectrum · 2019
    Review
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Erica BizzellEmory Vaccine Center, Emory University, Atlanta, Georgia, USA.
Jonathan Kevin SiaEmory Vaccine Center, Emory University, Atlanta, Georgia, USA.
Melanie QuezadaEmory Vaccine Center, Emory University, Atlanta, Georgia, USA.
Ana EnriquezEmory Vaccine Center, Emory University, Atlanta, Georgia, USA.
Maria GeorgievaEmory Vaccine Center, Emory University, Atlanta, Georgia, USA.
Jyothi RengarajanEmory Vaccine Center, Emory University, Atlanta, Georgia, USA.
Emory University · US

Funding

Yerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesisP51OD011132 · OD · EMORY UNIVERSITY · PI Joon Sup Lee · 2012 to 2026
$167.0M
YNPRC NHP CLINICAL MEDICINE RESIDENCY PROGRAM - SUPPLEMENTP51RR000165 · NCRR · EMORY UNIVERSITY · PI RENGARAJAN, JYOTHI · 1985 to 2011
$114.0M
Implementing a Maternal health and PRegnancy Outcomes Vision for Everyone (IMPROVE)UL1TR002378 · NCATS · EMORY UNIVERSITY · PI Andres J Garcia, Elizabeth O. Ofili · 2017 to 2026
$92.1M
Atlanta Clinical and Translational Science Institute (ACTSI) RenewalUL1TR000454 · NCATS · EMORY UNIVERSITY · PI STEPHENS, DAVID S · 2012 to 2016
$25.8M
Innate-adaptive crosstalk in protective and vaccine-induced immunity to TBR01AI134244 · NIAID · EMORY UNIVERSITY · PI RENGARAJAN, JYOTHI · 2017 to 2021
$3.4M
Modulation of Host Responses by Mycobacterium TuberculosisR01AI083366 · NIAID · EMORY UNIVERSITY · PI RENGARAJAN, JYOTHI · 2010 to 2014
$2.2M
Modulation of Host Responses by Mycobacterium tuberculosisR56AI083366 · NIAID · EMORY UNIVERSITY · PI RENGARAJAN, JYOTHI · 2016 to 2016
$542k
Targeting an immunomodulatory protease for adjunctive tuberculosis chemotherapyR21AI117162 · NIAID · EMORY UNIVERSITY · PI RENGARAJAN, JYOTHI · 2015 to 2016
$507k
NCATS NIH HHS UL1 TR000454NCATS NIH HHS UL1 TR002378NCRR NIH HHS P51 RR000165NIAID NIH HHS R01 AI083366NIAID NIH HHS R01 AI134244NIAID NIH HHS R21 AI117162NIAID NIH HHS R56 AI083366NIH HHS P51 OD011132
6 · The paper itself

Abstract

Dendritic cells (DCs) play a key role in the generation of CD4 T cell responses to pathogens. Mycobacterium tuberculosis (Mtb) harbors immune evasion mechanisms that impair DC responses and prevent optimal CD4 T cell immunity. The vaccine strain Mycobacterium bovis Bacille Calmette-Guérin (BCG) shares many of the immune evasion proteins utilized by Mtb, but the role of these proteins in DC and T cell responses elicited by BCG is poorly understood. We previously reported that the Mtb serine protease, Hip1, promotes sub-optimal DC responses during infection. Here, we tested the hypothesis that BCG Hip1 modulates DC functions and prevents optimal antigen-specific CD4 T cell responses that limit the immunogenicity of BCG. We generated a strain of BCG lacking hip1 (BCGΔhip1) and show that it has superior capacity to induce DC maturation and cytokine production compared with the parental BCG. Furthermore, BCGΔhip1-infected DCs were more effective at driving the production of IFN-γ and IL-17 from antigen-specific CD4 T cells in vitro. Mucosal transfer of BCGΔhip1-infected DCs into mouse lungs induced robust CD4 T cell activation in vivo and generated antigen-specific polyfunctional CD4 T cell responses in the lungs. Importantly, BCGΔhip1-infected DCs enhanced control of pulmonary bacterial burden following Mtb aerosol challenge compared with the transfer of BCG-infected DCs. These results reveal that BCG employs Hip1 to impair DC activation, leading to attenuated lung CD4 T cell responses with limited capacity to control Mtb burden after challenge.

Indexed as

Gene DeletionAnimalsBacterial ProteinsCD4-Positive T-LymphocytesCells, CulturedDendritic CellsMacrophagesMiceMice, Inbred C57BLMycobacterium bovisSerine ProteasesTuberculosisBacterial ProteinsHip1 protein, Mycobacterium tuberculosisSerine Proteasesimmune evasionimmunogenicitytuberculosisvaccine

Identifiers

PMID29345365
PMCPMC6457460
OpenAlexW2777096226

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.